Search In this Thesis
   Search In this Thesis  
العنوان
Comparative Study Of The Efficacy Of Intralesional Platelet-Rich Plasma Versus Steroid in Treatment Of Alopecia Areata /
المؤلف
Ibrahim, Maher Mahmoud Abdul Hameed.
هيئة الاعداد
باحث / ماهر محمود عبد الحميد إبراهيم
mailmaher@yahoo.com
مشرف / عبد العزيز إبراهيم الطويل
-
مشرف / عبد العزيز عبد السلام أحمد الرفاعي
-
مشرف / وليد محمد عبد المنعم البلاط
-
الموضوع
Alopecia areata. Baldness. Platelet-Rich Plasma Steroids.
تاريخ النشر
2017.
عدد الصفحات
156 p. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
الأمراض الجلدية
الناشر
تاريخ الإجازة
1/9/2017
مكان الإجازة
جامعة بني سويف - كلية الطب - الأمراض الجلدية والتناسلية وطب الذكورة
الفهرس
Only 14 pages are availabe for public view

from 155

from 155

Abstract

The aim of this study was to assess the efficacy and Complications of the use ofintralesional steroid versus platelet rich plasma, in treatment of alopecia areata
This study was conducted 80 patients of both sexes complaining of AA that have been subdivided to two groups. group I treated byintralesional triamcinolone acetonide. While group II treated byintralesional platelet rich plasma (PRP)(one session every two weeks).
The results were evaluated by photographs taken with the digital cameraat 1st session (base line), three and six months from the 1st session; and by the physician’s impressions.
According to Physician assessment of the clinical response to tttIn group (I) : 26 patients (65%) showed improvement > 70% after 12 weeks.
While in group (II)29 patients (72.5%) showed improvement > 70% after 12 weeks.
These results denoted that there is highly significant difference before and after ttt.
No serious or persistent side effects were detected except for the pain that was noticed only during the procedure in 50% of patients. It was quite tolerable with no need for analgesic aftertreatment or discontinuation of the sessions.
In the current study, by following up of the patients for six months after treatment with PRP we found that two (5%) of the patients had relapse of the disease.
While 10 (25 %) of the patients in the Triamcinolone A group had relapse of the disease.